Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 62Neoplasm Metastasis 10Stomach Neoplasms 9Brain Neoplasms 6Neoplasms 4HER2-positive Breast Cancer 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms, Male 4Lung Neoplasms 3Inflammatory Breast Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Meningeal Carcinomatosis 2Endometrial Neoplasms 2Central Nervous System Neoplasms 2Central Nervous System Diseases 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Solid Cancer 1Sarcoma 1Recurrence 1Pathologic Processes 1Ovarian Neoplasms 1Nervous System Neoplasms 1Nervous System Diseases 1Neoplastic Processes 1

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Bladder Urothelial Carcinoma × Trastuzumab × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡